# EDGAR Filing Document

**Accession Number:** 0001534248
**File Stem:** 0001178913-23-000147
**Filing Date:** 2023-1
**Character Count:** 6423
**Document Hash:** 69ad75f93839ee077d029ebd9f978a63
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-23-000147.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001178913-23-000147

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 49

**CONFORMED PERIOD OF REPORT**: 20230111

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chemomab Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001534248
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 813676773
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38807
- **FILM NUMBER:** 23523596

**BUSINESS ADDRESS:**
- **STREET 1:** KIRYAT ATIDIM, BUILDING 7
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6158002
- **BUSINESS PHONE:** 972-77-331-0156

**MAIL ADDRESS:**
- **STREET 1:** KIRYAT ATIDIM, BUILDING 7
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6158002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anchiano Therapeutics Ltd.
- **DATE OF NAME CHANGE:** 20180906

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioCancell Ltd.
- **DATE OF NAME CHANGE:** 20111104

------

 **UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 11, 2023**

**Chemomab Therapeutics Ltd.** 

**(Exact name of Registrant as Specified in Its Charter)**

---

| | | |
|:---|:---|:---|
| **State of Israel** | **001-38807**  | **81-3676773**  |
| **(State or Other Jurisdiction** | **(Commission** | **(IRS Employer** |
| **of Incorporation)** | **File Number)** | **Identification No.)** |

---

---

| | |
|:---|:---|
| **Kiryat Atidim, Building 7** |  |
| **Tel Aviv, Israel** | **6158002**  |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: +972-77-331-0156**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol(s)** | **Name of each <br> exchange<br> on which registered** |
| **American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share**  | **CMMB**  | **Nasdaq Capital Market**  |
| **Ordinary shares, no par value per share**  | **N/A** | **Nasdaq Capital Market\*** |

---

\* Not for trading; only in connection with the registration of American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated into this Item 7.01 by reference, is an updated corporate presentation of the Company.

#### Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Description** |
| [99.1](exhibit_99-1.htm) | [Corporate Presentation of Chemomab Therapeutics Ltd. (furnished herewith)](exhibit_99-1.htm) |

---

Exhibit 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CHEMOMAB THERAPEUTICS LTD.** | **CHEMOMAB THERAPEUTICS LTD.** |
| Date: January 11, 2023 | **By:** | /s/ Donald Marvin |
|  |  | Name: Donald Marvin |
|  |  | Title: Executive Vice President, Chief Financial Officer and Chief Operating Officer |

---

------

## Exhibit 99.1

------

<u>**Exhibit 99.1**</u><br>

 <u>**![](exhibit_99-1slide1.jpg)

------

![](exhibit_99-1slide2.jpg)

------

![](exhibit_99-1slide3.jpg)

------

![](exhibit_99-1slide4.jpg)

------

![](exhibit_99-1slide5.jpg)

------

![](exhibit_99-1slide6.jpg)

------

![](exhibit_99-1slide7.jpg)

------

![](exhibit_99-1slide8.jpg)

------

![](exhibit_99-1slide9.jpg)

------

![](exhibit_99-1slide10.jpg)

------

![](exhibit_99-1slide11.jpg)

------

![](exhibit_99-1slide12.jpg)

------

![](exhibit_99-1slide13.jpg)

------

![](exhibit_99-1slide14.jpg)

------

![](exhibit_99-1slide15.jpg)

------

![](exhibit_99-1slide16.jpg)

------

![](exhibit_99-1slide17.jpg)

------

![](exhibit_99-1slide18.jpg)

------

![](exhibit_99-1slide19.jpg)

------

![](exhibit_99-1slide20.jpg)

------

![](exhibit_99-1slide21.jpg)

------

![](exhibit_99-1slide22.jpg)

------

![](exhibit_99-1slide23.jpg)

------

![](exhibit_99-1slide24.jpg)

------

![](exhibit_99-1slide25.jpg)

------

![](exhibit_99-1slide26.jpg)

------

![](exhibit_99-1slide27.jpg)

------

![](exhibit_99-1slide28.jpg)

------

![](exhibit_99-1slide29.jpg)

------

![](exhibit_99-1slide30.jpg)

------

![](exhibit_99-1slide31.jpg)

------

![](exhibit_99-1slide32.jpg)

------

![](exhibit_99-1slide33.jpg)

------

![](exhibit_99-1slide34.jpg)

------

![](exhibit_99-1slide35.jpg)**</u> 

<br> ------

<br><u> </u>